I am also Director of the Wilson Auditory Brainstem Implant program based at the Mass. Eye and Ear and Mass. General Hospital. We offer the auditory brainstem implant (ABI) as an option for infants, children, and adults who are deaf and cannot receive the cochlear implant. We care for Neurofibromatosis Type 2 (NF2) patients who are deaf from bilateral vestibular schwannomas (acoustic neuromas) as well as pediatric and adult patients who are deaf from scarred inner ears, or absent or damaged auditory nerves. We have two FDA clinical trials on the ABI in both children and adults.
Clinically, the success rate of Intratympanic steroid therapy in patients with SHL is variable in the literature and the available studies are limited to retrospective and non-controlled prospective ones. In those studies steroids were used in various concentrations, regimens and delivery methods and their effectiveness have not been established due to the lack of randomized controlled trials. There have been some studies in the literature that discussed the effectiveness of Intratympanic steroid therapy as a salvage mode of therapy in patients who failed to respond to oral steroids (Herr & Marzo 2005, Slattery et al 2005).